Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23451515 | 0.98 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL19343385 | 0.83 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL17788625 | 0.81 | ALDH1A1 (0.56) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL13870638 | 0.80 | HDAC8 (0.67) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL8235977 | 0.79 | ALDH1A1 (0.67) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| Dimethylamine SCHEMBL9350461 | 0.78 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL11006387 | 0.78 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL28531581 | 0.78 | KMT2A (0.73) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL17790217 | 0.77 | GUSB (0.53) | RAB9ANPC1SMN1; SMN2HPGDTSHR | |
| SCHEMBL21303556 | 0.76 | MAPT (0.66) | RAB9ANPC1SMN1; SMN2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | RAB9A 1385/4885NPC1 4667/4885SMN1; SMN2 834/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | RAB9A 1162/4885NPC1 7/4885SMN1; SMN2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.